Optimized CLN1 Expression Cassettes for AAV-Mediated PPT1 Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are no effective treatments for infantile neuronal ceroid lipofuscinosis (INCL), an autosomal recessive disorder caused by mutations in the CLN1 gene, which leads to excessive accumulation of lipopigments in neuronal cells, resulting in neurodegeneration.

Innovation Solution

Development of optimized CLN1 genes and expression cassettes, including codon-optimized polynucleotides encoding PPT1 polypeptides, delivered via vectors to provide therapeutic levels of expression, potentially using AAV vectors to target CNS cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If enzyme replacement therapy is administered to treat INCL, then some therapeutic effect may be achieved, but the clinical efficacy is insufficient and the treatment is not effective

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoiddisease progression rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent uses AAV vectors as intermediaries to deliver the CLN1 gene directly to neuronal cells, bypassing the limitations of enzyme replacement therapy. The viral vector acts as a mediator to achieve sustained intracellular expression of functional PPT1 enzyme, thereby improving therapeutic efficacy and preventing disease progression more effectively than exogenous enzyme administration alone.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If gene therapy approaches are attempted to treat INCL, then potential curative effects may be achieved, but the methods lack optimized expression systems for effective therapeutic levels

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidexpression system complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent optimizes the CLN1 gene expression system by modifying promoter strength, codon usage, and vector design parameters to achieve therapeutic levels of PPT1 enzyme expression. These parameter changes enable effective gene therapy while managing the complexity of the expression system through systematic optimization rather than trial-and-error approaches.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If neural stem cells and other agents are administered to treat INCL, then some disease modification may occur, but the clinical efficacy remains under study and is not yet established

Engineering Contradiction:

Improveclinical efficacyVSAvoidtime for efficacy evaluation

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent employs preliminary action by using AAV-mediated gene delivery to establish sustained PPT1 enzyme production before significant neuronal damage occurs. This proactive approach prevents disease progression rather than attempting to reverse established damage, reducing the time needed to observe clinical efficacy compared to therapies that attempt to repair already-damaged neurons.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20260077064A1Optimized CLN1 genes and expression cassettes and their use

Publication Date: 2026.03.19 THE UNIV OF NORTH CAROLINA AT CHAPEL HILL

AI summary

This invention relates to polynucleotides comprising a nucleotide sequence encoding a PPT1 polypeptide or a fragment thereof, vectors (viral or non-viral vectors) comprising the same, and methods of using the same for delivery of the open reading frame to a cell or a subject and to treat infantile neuronal lipofuscinosis (infantile Batten disease). The polynucleotides comprise an optimized CLN1 open reading frame.